Vericiguat Medicine 10 December 2019 Extended indication Hartfalen met verminderde ejectiefractie (HFrEF) Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Vericiguat Domain Cardiovascular diseases Reason of inclusion New medicine (specialité) Main indication Other medication for cardiovascular diseases Extended indication Hartfalen met verminderde ejectiefractie (HFrEF) Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Bayer Portfolio holder Mechanism of action Other, see general comments Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Stimulator van het soluble guanylate cyclase (sGC) enzym. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date July 2020 Expected Registration August 2021 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Patiënten met HErEF ontvangen veel verschillende soorten medicatie. Voorbeelden hiervan zijn: ''81% of the patients were treated with loop diuretics, 84% with renin-angiotensin-system (RAS) inhibitors, 86% with β-blockers, 56% with mineralocorticoid-receptor antagonists (MRA), and 5% with If-channel inhibition.'' (Brunner-La Rocca et al. , 2019) Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Patiënten met HErEF ontvangen al veel medicatie, vericiguat zal naast deze medicatie voorgeschreven worden. Duration of treatment Frequency of administration 1 times a day Dosage per administration 2,5, 5 of 10 mg References NCT02861534 Brunner-La Rocca et al. (2019). Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 7(1), 13-21. doi: 10.1016/j.jchf.2018.10.010 Additional remarks Expected patient volume per year Patient volume < 3,000 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Patiënten met HErEF ontvangen veel verschillende soorten medicatie, Vericiguat zal hier nog bovenop komen. Het patiëntaantal zal naar verwachting niet hoger liggen dan 3.000 patiënten per jaar (vergelijkbaar met entresto). Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions No Indication extensions References Additional remarks Other information Additional remarks